Disease / condition
Diabetes,Diabetes Mellitus, Type 2 clinical trials
Free access to 335 studies10+ countriesUpdated daily1 recruiting
VerifiedClinicalTrials.gov · WHO ICTRP · regional registries
335
Total trials
10+
Countries
3+
Sponsors
1
Recruiting
By phase
Phase 3130
N/A78
Phase 463
Phase 145
Phase 219
By status
Completed318
Terminated13
Withdrawn2
Recruiting1
Not yet recruit...1
Top countries
Japan29
Germany25
United States of America23
China23
Denmark8
Top sponsors
Novo Nordisk A/S332
Emory University2
MedsPLUS Consultin...1
Recent trials
Latest clinical trials for Diabetes,Diabetes Mellitus, Type 2
Improving Recruitment and Retention for Diabetes Self-Management Education and Support
MedsPLUS Consulting
NCT05958602Not yet recr...
Dexcom CGM in Long-term Care
Emory University · United States of America
NCT04818242Recruiting
Mindfulness IN-home for Diabetes and Sleep Health
Emory University · United States of America
NCT04160078Completed
A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
Novo Nordisk A/S · Germany
NCT03466567Completed
- Phase
- Phase 1
A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)
Novo Nordisk A/S · India
NCT03374774Completed
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
Novo Nordisk A/S · China
NCT03292185Completed
- Phase
- Phase 1
A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects
Novo Nordisk A/S · China
NCT03288740Completed
- Phase
- Phase 1
Research Study Comparing a New Medicine Fast-acting Insulin Aspart to Another Already Available Medicine NovoRapid/NovoLog in People With Type 2 Diabetes
Novo Nordisk A/S · Argentina,Bulgaria,Canada,Croatia,Czech,Germany,Greece,Italy,South Korea,Poland,Puerto Rico,Romania,
NCT03268005Completed
- Phase
- Phase 3
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
Novo Nordisk A/S · Bulgaria,Czech,Finland,France,Germany,Hungary,Italy,Poland,Slovenia,Spain,Sweden,United Kingdom
NCT03191396Completed
- Phase
- Phase 3
A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
Novo Nordisk A/S · China,China
NCT03175120Completed
- Phase
- Phase 3
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
Novo Nordisk A/S · China
NCT03172494Completed
- Phase
- Phase 3
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
Novo Nordisk A/S · Argentina,Brazil,Canada,India,Ireland,Italy,Lebanon,Malaysia,Mexico,Sweden,United Kingdom,United Sta
NCT03136484Completed
- Phase
- Phase 3
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S · Austria,Canada,Japan,Norway,Puerto Rico,Russian Federation,United States of America
NCT03086330Completed
- Phase
- Phase 3
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
Novo Nordisk A/S · Canada,Denmark,Estonia,Germany,Greece,Hungary,Norway,Poland,Puerto Rico,Romania,Serbia,United States
NCT03078478Completed
- Phase
- Phase 3
Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India
Novo Nordisk A/S
NCT03070704Withdrawn
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
Novo Nordisk A/S · Brazil,China,China,South Korea,South Africa,Taiwan,Ukraine
NCT03061214Completed
- Phase
- Phase 3
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
Novo Nordisk A/S · Canada,France,Greece,India,Japan,Mexico,Poland,Puerto Rico,Russian Federation,United States of Ameri
NCT03021187Completed
- Phase
- Phase 3
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/S · Japan
NCT03018028Completed
- Phase
- Phase 3
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/S · Japan
NCT03015220Completed
- Phase
- Phase 3
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
Novo Nordisk A/S · Brazil,India,Israel,Puerto Rico,Russian Federation,United Arab Emirates,United States of America
NCT02964247Completed
- Phase
- Phase 3
About this profile
Access comprehensive clinical trial information for Diabetes,Diabetes Mellitus, Type 2 through Pure Global AI's free database. This collection includes 335 clinical trials across multiple phases including Phase 3, N/A, Phase 4. Currently, 1 trials are actively recruiting participants.
Research for Diabetes,Diabetes Mellitus, Type 2 is being conducted in Japan, Germany, United States of America and 7+ other countries. Leading sponsors include Novo Nordisk A/S and Emory University. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.
Pure Global AI provides free access to 335 clinical trials studying Diabetes,Diabetes Mellitus, Type 2, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.
The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.
Top research sponsors include Novo Nordisk A/S, Emory University, MedsPLUS Consulting, among others.